Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Gastrointestinal 1

Conditions

Endometrial Adenocarcinoma 1

Interventions

Radiotherapy 34Gemcitabine 24Docetaxel 24bicalutamide 23Goserelin 21Paclitaxel 19Cisplatin 19Doxorubicin 18Carboplatin 18Flutamide 17Leuprolide 16Radiotherapy, Conformal 13Etoposide 13Filgrastim 12Prednisone 11Gene Expression Profiling 11Gonadotropin-Releasing Hormone 10Radiotherapy, Intensity-Modulated 9Vincristine 8Vinblastine 8Triptorelin Pamoate 8Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Buserelin 8Androgen Antagonists 8Surgical Procedures, Operative 7Radiation 7Polymerase Chain Reaction 7Methotrexate 7Estramustine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × brivanib × Genitourinary × Clear all
NCT00888173 2017-12-06

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
45 enrolled 10 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡